MLYS

Mineralys Therapeutics, Inc. · NASDAQ

Performance

-2.59%

1W

-6.41%

1M

+10.98%

3M

-0.0%

6M

+52.79%

YTD

+87.18%

1Y

Profile

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Technical Analysis of MLYS 2024-12-10

The stock exhibits a strong bullish sentiment with a Moving Average Score of 90, indicating robust upward momentum, while the Technical Score of 68 further supports this positive outlook. However, the Oscillators Score of 46 suggests a neutral stance, indicating potential consolidation or a pause in the upward trend, which investors should monit...
Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

See more ...

Stock Analysis of MLYS

Stock Rank

See more ...

Recent News & Updates

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.